Sorted by: Date | Title

Galindo News

A new, faster route for pediatric clinical trials

July 13, 2010
Researchers hoping to test promising cancer therapies for children now have an easier way to navigate the forest of funding applications, regulatory rules, hiring procedures, review boards, statistical services, and other logistical requirements.
David Williams, MD

Williams honored for Outstanding Achievement by ASGCT

January 23, 2012
Congratulations to David Williams, MD, chief of the Division of Hematology/Oncology and director of Translational Research at Children's, and associate chair of Pediatric Oncology at Dana-Farber Cancer Institute, who has been selected by the American Society of Gene & Cell Therapy as the recipient of their 2012 Outstanding Achievement Award.

Justin Bieber Dream Date Shines Light on Rare Pediatric Cancer

February 14, 2012
Avalanna Routh celebrated Valentine's Day this year with a date for the ages. The six-year-old Dana-Farber Boston Children's Cancer and Blood Disorders Center patient, who has been diagnosed with a rare brain tumor, went on a "dream date" with Justin Bieber, thanks in part to a Facebook campaign to have Routh meet the pop star. As important as the date itself, however, is the attention it has focused on atypical teratoid rhabdoid tumor, or AT/RT.

American Association for Cancer Research honors D'Andrea

April 06, 2012
The American Association for Cancer Research presented Alan D. D'Andrea, MD, the Alvan T. and Viola D. Fuller American Cancer Society professor of radiation oncology at the Dana-Farber Cancer Institute and Harvard Medical School, with the 52nd Annual AACR G.H.A. Clowes Memorial Award for his work in understanding cancer survival and progression, which has included milestones such as cloning the erythropoietin receptor and discovering the Fanconi anemia family of proteins involved in maintaining DNA stability.

Key mutations discovered for most common childhood brain cancer

July 23, 2012
Findings could enable individualized treatment for patients with medulloblastoma Researchers at Dana-Farber Boston Children's Cancer and Blood Disorders Center and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

Dana-Farber/Children's Hospital Cancer Center establishes training program with Egypt Cancer Network and Children's Cancer Hospital Egypt

September 21, 2012
Egypt-based program for physicians from Egypt, the Middle East and North Africa Dana-Farber/Children's Hospital Cancer Center is announcing a partnership with the Egypt Cancer Network and Children's Cancer Hospital Egypt in an effort to improve childhood cancer survival rates and outcomes within Egypt, the Middle East and North Africa. The organizations are collaborating to create an Egypt-based fellowship training program in pediatric oncology for physicians in those regions.

Intensified chemotherapy shows promise for children with very high-risk form of leukemia

December 10, 2012
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber Boston Children's Cancer and Blood Disorders Center in Boston.

National Academy of Sciences honors Dana-Farber Boston Children's Cancer and Blood Disorders Center's Orkin

January 15, 2013
Stuart H. Orkin, MD, chairman of the department of pediatric oncology at Dana-Farber Boston Children's Cancer and Blood Disorders Center, will receive the Jessie Stevenson Kovalenko Medal at the National Academy of Sciences' 150th Annual meeting in April.

Alex's Lemonade Stand Foundation awards $1.75 million grant to Dana-Farber Boston Children's Cancer and Blood Disorders Center

January 30, 2013
Alex's Lemonade Stand Foundation (ALSF) is furthering its commitment to finding cures for all kids with cancer by introducing the ALSF Centers of Excellence program. Dana-Farber Boston Children's Cancer and Blood Disorders Center is one of the first three institutions to be named as a Center of Excellence and will receive funding of $350,000 per year, renewable annually for up to five years for a total of $1.75 million. The other recipients are Baylor College of Medicine and the University of California San Francisco.

Delays in diagnosis worsen outlook for minority, uninsured pediatric retinoblastoma patients, study finds

April 27, 2013
When the eye cancer retinoblastoma is diagnosed in racial and ethnic minority children whose families don’t have private health insurance, it often takes a more invasive, potentially life-threatening course than in other children, probably because of delays in diagnosis.
Showing 1-10 of 138 items